Methods and compositions for treating hepatitis C virus
View Patent ↗A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
1. A method for the treatment of a hepatitis C virus infection, comprising administering an effective amount of a purine or pyrimidine β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
2. The method of claim 1 , wherein the nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is a pyrimidine nucleoside.
3. The method of claim 1 , wherein the nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is a purine nucleoside.
4. The method of claim 1 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a phannaceutically acceptable salt or ester thereof is administered in combination or alternation with a second anti-hepatitis C agent.
5. The method of claim 4 , wherein the second agent is selected from the group consisting of an interferon, ribavirin, a protease inhibitor, a thaizolidine derivative, a polymerase inhibitor, and a helicase inhibitor.
6. The method of claim 5 , wherein the second agent is an interferon.
7. The method of claim 5 , wherein the second agent is an ribavirin.
8. The method of claim 1 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester is in the form of a dosage unit.
9. The method of claim 8 , wherein the dosage unit contains 50 to 1000 mg.
10. The method of claim 8 , wherein the dosage unit is a tablet or capsule.
11. The method of claim 1 , wherein the βD-2′-methyl-ribofuranosyl nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is in substantially pure form.
12. The method of claim 11 , wherein the βD-2′-methyl-ribofuranosyl nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is at least 90% by weight of the β-D-isomer.
13. The method of claim 11 , wherein the βD-2′-methyl-ribofuranosyl nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is at least 95% by weight of the βD-isomer.
14. The method of claim 1 , wherein the βD-2′-methyl-ribofuranosyl nucleoside is administered.
15. The method of claim 1 , wherein the βD-2′-methyl-ribofuranosyl nucleoside is administered in the form of a pharmaceutically acceptable salt.
16. The method of claim 1 , wherein the βD-2′-methyl-ribofuranosyl nucleoside is administered in the form of a pharmaceutically acceptable ester.
17. The method of claim 14 , wherein the nucleoside is a pyrimidine nucleoside.
18. The method of claim 15 , wherein the nucleoside is a pyrimidine nucleoside.
19. The method of claim 16 , wherein the nucleoside is a pyrimidine nucleoside.
20. The method of claim 14 , wherein the nucleoside is a purine nucleoside.
21. The method of claim 15 , wherein the nucleoside is a purine nucleoside.
22. The method of claim 16 , wherein the nucleoside is a purine nucleoside.
23. The method of claim 1 , wherein a phosphate, or a pharmaceutically acceptable salt thereof, of the β-D-2′-methyl-ribofuranosyl nucleoside is administered.
24. The method of claim 2 , wherein the pyrimidine nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is a cytidine nucleoside.
25. The method of claim 3 , wherein the purine nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is a guanosine nucleoside.
26. The method of claim 24 , wherein a phosphate, or a pharmaceutically acceptable salt thereof, of the cytidine nucleoside is administered.
27. The method of claim 25 , wherein a phosphate, or a pharmaceutically acceptable salt thereof, of the guanosine nucleoside is administered.
28. The method of claim 1 , wherein the nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is administered to a host.
29. The method of claim 28 , wherein the host is a human.
30. A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a hepatitis C virus in the host with a compound of claim 1 or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
31. A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a cell in the host infected with a hepatitis C virus with a compound of claim 1 or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
32. A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a hepatitis C virus in the host with a compound of claim 24 or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
33. A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a cell in the host infected with a hepatitis C virus with a compound of claim 25 or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.